RNA Biotechs: Current State And Outlook

2025-03-28 09:00:39 ET

Summary

• RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with stability and specificity.
• Alnylam, Ionis, and Sarepta lead the RNA therapeutics market, with Alnylam showing the most promise due to superior delivery technologies.
• Profitability remains a challenge for RNA therapeutics, but tech advancements and targeting rare diseases offer significant growth potential.
• The RNA biotech sector is at a proof-of-concept stage, with future success dependent on continued innovation and academic-business cooperation.

Introduction

Ribonucleic acid, or RNA, was long overshadowed by the more stable counterpart, DNA. However, advances in detection and other technologies have come to show that RNA is far more influential to the day-to-day operations of all organisms. This is because while DNA certainly is critical in storing the necessary genetic information, RNA is used for informational, enzymatic, and regulatory roles. For example, ribosomes, the units responsible for protein synthesis, are partly made up of RNA and small differences in environmental conditions can influence translation. The subclasses of non-coding RNA (ncRNA) composed of miRNA, siRNA, cirRNA, tRNA, rRNA, etc, are the key machinery of genetic expression in cells. For this reason, these RNAs have been deeply studied for therapeutic purposes, and will be the focus of this article. Other famous mRNA vaccines tech and genetic engineering RNA techniques like CRISPR/Cas will be covered separately....

Read the full article on Seeking Alpha

For further details see: